IPCA Laboratories Limited
IPCALAB · Pharma · NSE
₹1,457
Current Market Price
Fair Value (DCF)
₹1,136
Margin of Safety
-22.0%
Updated 1d ago
YieldIQ Score
56/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
47%
ROE
8.8%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.37 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
13.0%
Return on capital employed
EV / EBITDA
21.8×
Enterprise multiple
Debt / EBITDA
0.7×
Leverage vs earnings
Interest Coverage
14.4×
EBIT covers interest
Current Ratio
2.63×
Short-term liquidity
Asset Turnover
0.77×
Revenue per ₹ of assets
Revenue CAGR (3Y)
14.7%
3-year revenue growth
Revenue CAGR (5Y)
11.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,456.8
Bear case
₹670.86
MoS -117.2%
Base case
₹1,136.14
MoS -28.2%
Bull case
₹1,565.22
MoS +6.9%
Ratio Trends
IPCALAB · last 8 annual periods
ROE
8.8%
ROCE
16.5%
Operating Margin
—
Debt / Equity
0.16×
PE
42.9×
EV / EBITDA
19.1×
Historical Financials
IPCALAB · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹5420 Cr | ₹5830 Cr | ₹6244 Cr | ₹7705 Cr | ₹8855 Cr | +13.1% |
| EBITDA | — | ₹1375 Cr | ₹1052 Cr | ₹1337 Cr | ₹1613 Cr | +4.1% |
| EBIT | ₹1398 Cr | ₹1143 Cr | ₹791 Cr | ₹981 Cr | — | -8.5% |
| PAT | ₹1141 Cr | ₹890 Cr | ₹479 Cr | ₹523 Cr | ₹738 Cr | -10.3% |
| EPS (diluted) | ₹90.11 | ₹34.85 | ₹18.58 | ₹21.57 | — | -30.1% |
| CFO | ₹1090 Cr | ₹856 Cr | ₹806 Cr | ₹945 Cr | ₹1321 Cr | +4.9% |
| CapEx | — | — | — | — | ₹-776 Cr | — |
| FCF | — | — | — | — | ₹546 Cr | +0.0% |
| Total Assets | — | ₹7624 Cr | ₹8626 Cr | ₹11.1K Cr | ₹11.8K Cr | +11.4% |
| Total Debt | — | — | ₹806 Cr | ₹807 Cr | ₹1363 Cr | +14.0% |
| Shareholders' Equity | — | — | ₹5842 Cr | ₹6332 Cr | ₹8388 Cr | +9.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
IPCALAB vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| AJANTPHARM Ajanta Pharma Limited | -32.4% | 58 | Above Fair Value | 24.3% | — |
| JBCHEPHARM JBCHEPHARM | — | — | Pending | 19.2% | — |
| EMCURE Emcure Pharmaceuticals Limited | -41.7% | 50 | Above Fair Value | 14.7% | — |
| GLAND Gland Pharma Limited | -12.7% | 64 | Near Fair Value | 7.6% | — |
| ABBOTINDIA Abbott India Limited | -12.5% | 63 | Near Fair Value | 33.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
11 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹16.00/sh
Last payout
2025-08-05
₹2.00
Peak payout
₹4.00
Trailing yield
0.14%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. IPCA Laboratories Limited (IPCALAB.NS) trades at 1456.80 vs a model fair value of 1136.14, a gap of -22.0%. Piotroski F-score: 6/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of IPCALAB →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for IPCALAB →
Compare
Head-to-head with peers
Compare IPCALAB side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse IPCALABNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.